These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34918440)

  • 1. Parathormone enhances eryptosis in patients with end stage renal disease treated by hemodialysis.
    Hefny A; Fikry AA; Zahran MH; Shendi AM
    Hemodial Int; 2022 Apr; 26(2):234-242. PubMed ID: 34918440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of eryptosis in patients with chronic kidney disease.
    Gok MG; Paydas S; Boral B; Onan E; Kaya B
    Int Urol Nephrol; 2022 Nov; 54(11):2919-2928. PubMed ID: 35469112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suicidal erythrocyte death in end-stage renal disease.
    Abed M; Artunc F; Alzoubi K; Honisch S; Baumann D; Föller M; Lang F
    J Mol Med (Berl); 2014 Aug; 92(8):871-9. PubMed ID: 24743961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium.
    Dimitrakov D; Koumtchev E; Dimitrova R; Stavrev P
    Folia Med (Plovdiv); 1998; 40(4):48-53. PubMed ID: 10371800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uremia and Inadequate Oxygen Supply Induce Eryptosis and Intracellular Hypoxia in Red Blood Cells.
    Dias GF; Tozoni SS; Bohnen G; Grobe N; Rodrigues SD; Meireles T; Nakao LS; Pecoits-Filho R; Kotanko P; Moreno-Amaral AN
    Cell Physiol Biochem; 2021 Jul; 55(4):449-459. PubMed ID: 34259420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eryptosis - the Neglected Cause of Anemia in End Stage Renal Disease.
    Lang F; Bissinger R; Abed M; Artunc F
    Kidney Blood Press Res; 2017; 42(4):749-760. PubMed ID: 29151105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism.
    Sanadgol H; Bayani M; Mohammadi M; Bayani B; Mashhadi MA
    Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Induction of Eryptosis by Uremic Toxins and Inflammation Mediators in Healthy Red Blood Cells.
    Virzì GM; Mattiotti M; Clementi A; Milan Manani S; Battaglia GG; Ronco C; Zanella M
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender.
    Indridason OS; Pieper CF; Quarles LD
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3860-6. PubMed ID: 9814459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eryptosis: a driver of anemia in chronic kidney disease.
    Bissinger R; Qadri SM; Artunc F
    Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):220-225. PubMed ID: 37987655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between pruritus and serum concentrations of parathormone, calcium and phosphorus in hemodialysis patients.
    Tajbakhsh R; Joshaghani HR; Bayzayi F; Haddad M; Qorbani M
    Saudi J Kidney Dis Transpl; 2013 Jul; 24(4):702-6. PubMed ID: 23816717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).
    Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL;
    Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.